Last reviewed · How we verify
Faricimab Injection [Vabysmo] — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Faricimab Injection [Vabysmo] (Faricimab Injection [Vabysmo]) — Junyeop Lee.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Faricimab Injection [Vabysmo] TARGET | Faricimab Injection [Vabysmo] | Junyeop Lee | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Faricimab Injection [Vabysmo] CI watch — RSS
- Faricimab Injection [Vabysmo] CI watch — Atom
- Faricimab Injection [Vabysmo] CI watch — JSON
- Faricimab Injection [Vabysmo] alone — RSS
Cite this brief
Drug Landscape (2026). Faricimab Injection [Vabysmo] — Competitive Intelligence Brief. https://druglandscape.com/ci/faricimab-injection-vabysmo. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing